clear glass jar with multi colored heart shaped candies
  • Bimekizumab-bkzx Shows Prolonged Efficacy in Psoriasis Treatment Over Four Years
  • High Rates of Complete Skin Clearance Maintained; Safety Profile Consistent

San Diego, California — UCB, a prominent global biopharmaceutical company, said Saturday four-year data for BIMZELX showed sustained efficacy and safety in treating adults with moderate to severe plaque psoriasis.

Psoriasis is one of the most common inflammatory diseases of the skin. It usually progresses in episodes. Typical signs are red, scaly patches that stand out sharply from the healthy skin and are often very itchy.

New Findings

The new findings were highlighted at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California.

The late-breaking platform presentation at AAD demonstrated that bimekizumab-bkzx rapidly achieved and maintained significant clinical and health-related quality-of-life responses over a four-year span. Notably, 60% of patients achieved complete skin clearance (PASI100) by the fourth year. Responder analyses further indicated that about 90% of patients who reached PASI90 at Week 16, and over 70% who attained PASI100, successfully maintained their responses up to the fourth year.

Dr. Bruce Strober, Clinical Professor of Dermatology at Yale University, and Central Connecticut Dermatology, Connecticut, U.S.:

“Moderate to severe plaque psoriasis is a chronic condition with physical skin manifestations that can place a significant burden on a patient’s health-related quality-of-life. Analysis shows that through four years of bimekizumab-bkzx treatment, over six out of ten patients achieved and maintained complete skin clearance, a clinically meaningful endpoint and outcome for patients. These long-term data will be highly welcomed by the dermatology community since they provide important considerations for clinical practice.”

Long-term Results “encouraging”

These long-term results are especially encouraging for the psoriasis community, as they suggest a durable treatment option that can offer lasting relief. The four-year safety data for bimekizumab-bkzx was also encouraging, showing that treatment-emergent adverse events were either consistent or decreased over time, with no new safety concerns arising.

By Lisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *

GDPR Cookie Consent with Real Cookie Banner